Körner H, Lemckert F A, Chaudhri G, Etteldorf S, Sedgwick J D
Centenary Institute of Cancer Medicine and Cell Biology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Eur J Immunol. 1997 Aug;27(8):1973-81. doi: 10.1002/eji.1830270822.
Recently, we demonstrated that experimental autoimmune encephalomyelitis (EAE) in the rat, passively transferred using myelin basic protein (MBP)-reactive encephalitogenic CD4+ T cells, was preventable by administration of a p55-tumor necrosis factor-IgG fusion protein (TNFR-IgG). This was despite quantitatively and qualitatively normal movement of these MBP-specific T cells to the central nervous system (CNS). To extend these findings, the effect of TNFR-IgG on EAE actively induced by injection of MBP in complete Freund's adjuvant was examined. This form of EAE in the rat typically involves an acute, self-limiting neurological deficit, substantial CNS inflammation, but minimal demyelination. Here we show that administration of TNFR-IgG prior to onset of disease signs completely prevented the neurological deficit or markedly reduced its severity. This blockade of clinical disease was dissociated from weight loss which occurred at the same tempo and magnitude as in control rats exhibiting neurological signs of disease such as paralysis. The timing of TNF blockade was critical as established clinical disease was relatively refractory to TNFR-IgG treatment. Activated CD4+ T cells expressing normal or elevated levels of VLA4, major histocompatibility complex class II, MRC OX40 and CD25 were isolated from or immunohistochemically localized in the CNS of clinically healthy rats treated before disease onset. There was a reduction of the amount of other inflammatory leukocytes in the CNS of these treated animals but, more importantly, the activation state of inflammatory leukocytes, as well as that of microglia isolated from treated animals, was reduced. Thus, TNFR-IgG, when administered before disease onset, appears to act by inhibiting an effector function of activated T cells and possibly other inflammatory leukocytes necessary to bring about the neurological deficit. However, while TNF is a critically important cytokine for the early events leading to initiation of EAE, it is not a necessary factor in the acute neurological deficit characteristic of this form of EAE, once disease onset has occurred.
最近,我们证明,使用髓鞘碱性蛋白(MBP)反应性致脑炎性CD4+T细胞被动转移的大鼠实验性自身免疫性脑脊髓炎(EAE),可通过给予p55-肿瘤坏死因子-IgG融合蛋白(TNFR-IgG)来预防。尽管这些MBP特异性T细胞向中枢神经系统(CNS)的定量和定性运动正常。为了扩展这些发现,研究了TNFR-IgG对在完全弗氏佐剂中注射MBP主动诱导的EAE的影响。大鼠的这种EAE形式通常涉及急性、自限性神经功能缺损、大量CNS炎症,但脱髓鞘程度最小。在这里我们表明,在疾病体征出现之前给予TNFR-IgG可完全预防神经功能缺损或显著降低其严重程度。这种对临床疾病的阻断与体重减轻无关,体重减轻的速度和幅度与出现疾病神经体征(如瘫痪)的对照大鼠相同。TNF阻断的时机至关重要,因为已确立的临床疾病对TNFR-IgG治疗相对难治。从疾病发作前接受治疗的临床健康大鼠的CNS中分离出或通过免疫组织化学定位表达正常或升高水平的VLA4、主要组织相容性复合体II类、MRC OX40和CD25的活化CD4+T细胞。这些接受治疗的动物的CNS中其他炎性白细胞的数量减少,但更重要的是,炎性白细胞以及从接受治疗的动物中分离出的小胶质细胞的活化状态降低。因此,TNFR-IgG在疾病发作前给予时,似乎通过抑制活化T细胞以及可能导致神经功能缺损所必需的其他炎性白细胞的效应功能来发挥作用。然而,虽然TNF是导致EAE起始的早期事件的关键重要细胞因子,但一旦疾病发作,它并不是这种EAE形式的急性神经功能缺损的必要因素。